Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway

Torbjørn Wisløff (), Richard White, Olav Dalgard, Ellen J. Amundsen, Hinta Meijerink, Astrid Louise Løvlie and Hilde Kløvstad
Additional contact information
Torbjørn Wisløff: Norwegian Institute of Public Health
Richard White: Norwegian Institute of Public Health
Olav Dalgard: Akershus University Hospital
Ellen J. Amundsen: Norwegian Institute of Public Health
Hinta Meijerink: Norwegian Institute of Public Health
Astrid Louise Løvlie: Norwegian Institute of Public Health
Hilde Kløvstad: Norwegian Institute of Public Health

PharmacoEconomics, 2018, vol. 36, issue 5, No 7, 601 pages

Abstract: Abstract Purpose New direct-acting antiviral (DAA) drugs have revolutionized the treatment of hepatitis C in recent years. Objective Our objective was to analyse the cost effectiveness of combinations of different DAAs compared with ribavirin and peginterferon-α-2a, taking into account rebates from tender negotiations. Methods We used a compartmental model specifically developed for Norway to simulate hepatitis C and complications with and without different DAAs. All costs were based on Norwegian fees and estimates, estimating healthcare sector costs for the year 2016. We performed Monte Carlo simulations on uncertain input parameters to facilitate probabilistic sensitivity analyses. Results For patients diagnosed with genotype 1, the combination of paritaprevir, ritonavir, ombitasvir and dasabuvir was cost effective compared with eight other available alternatives, given a cost-effectiveness threshold of €70,000 per quality-adjusted life-year. For genotype 2, the combination of sofosbuvir and ribavirin was the most effective and cost-effective alternative for all patients. Among available alternatives for patients with genotype 3, sofosbuvir in combination with peginterferon and ribavirin was the most cost-effective alternative, although the combination of daclatasvir and sofosbuvir was somewhat more effective. Conclusions For each of the hepatitis C genotypes 1, 2 and 3, there were combinations of DAAs that were cost effective in a Norwegian setting. As a result of recent tender negotiations in Norway, treating all diagnosed patients with hepatitis C with the most cost-effective DAAs will result in lower total expenditure on these medications compared with 2015.

Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-017-0604-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:36:y:2018:i:5:d:10.1007_s40273-017-0604-3

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-017-0604-3

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().